Savara Inc. (SVRA)
 NASDAQ: SVRA · Real-Time Price · USD
 4.250
 -0.050 (-1.16%)
  Oct 31, 2025, 12:15 PM EDT - Market open
Savara Revenue
Revenue (ttm) 
 n/a
Revenue Growth 
 n/a
P/S Ratio 
 n/a
Revenue / Employee 
 n/a
Employees 
 59
Market Cap 
895.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | - | - | - | 
| Dec 31, 2023 | - | - | - | 
| Dec 31, 2022 | - | - | - | 
| Dec 31, 2021 | - | - | - | 
| Dec 31, 2020 | 257.00K | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
SVRA News
- 1 day ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - GlobeNewsWire
- 1 day ago - Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants - Business Wire
- 1 day ago - Savara Announces Proposed Public Offering - Business Wire
- 1 day ago - Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 3 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - PRNewsWire
- 7 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - PRNewsWire
- 14 days ago - Savara Announces Chief Medical Officer (CMO) Transition - Business Wire
- 17 days ago - SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline - GlobeNewsWire